Alagille Syndrome Market Highlights
Global Alagille Syndrome Market is expected to grow significantly over the forecast period. Alagille syndrome is a rare genetic condition that can affect the liver and other parts of the body. An individual having alagille syndrome has a fewer number of small bile ducts inside the liver.
This causes the bile to build-up inside the liver, which in turn causes liver scarring and damage. Moreover, the signs and symptoms of this syndrome are generally noticed in infancy or early childhood.
The growing occurrence of alagille syndrome, increasing healthcare expenditure, and rising prevalence of genetic diseases are anticipated to drive the growth of the market. According to the US National Library of Medicine, the estimated prevalence of alagille syndrome is 1 in 70,000 newborns.
Key Players Overview
Sanofi AG, Teva Pharmaceutical Industries Ltd., Allergen Plc, Lannett, Albireo Pharma, Inc., AstraZeneca Plc, Novartis AG, Pfizer, Inc., Shire, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc. are some of the key players in the global alagille syndrome market.
Get Exclusive Sample Report @ https://www.marketresearchfuture.com/sample_request/6324
The Global Alagille Syndrome Market has been segmented into symptom, treatment, diagnosis, and end-user.
The market on the basis of symptom has been segmented into liver problems, nutrition problems, heart problems, distinctive facial features, neurologic problems, and others.
The market, by treatment, has been segmented into medication, biliary diversion procedures, vitamin supplements, liver transplantation, kidney surgery, heart surgery, and others. The medication segment has been further segmented into Ursodeoxycholic acid, cholestyramine, rifampin, naltrexone, and anti-histamine. The anti-histamine segment has been further segmented into hydroxyzine and others.
The market, by diagnosis, has been segmented into blood test, urinalysis, X-ray imaging, cardiology exam, slit-lamp exam, liver biopsy, genetic testing, prenatal DNA testing, and others.
On the basis of end-user, the market has been segmented into hospitals and clinics, diagnostic centers, and others.
The Alagille Syndrome Market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The alagille syndrome market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European alagille syndrome market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The alagille syndrome market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The alagille syndrome market in the Middle East & Africa has been segmented into the Middle East and Africa.
Geographical Analysis of Major Regions
Geographically, the Americas is anticipated to dominate the global alagille syndrome market owing to a well-developed healthcare sector, rising prevalence of rare genetic disease and growing healthcare expenditure. According to the Global Genes Project, rare and genetic diseases affect 1 in 10 people in the United States Additionally, increasing awareness among the people regarding the disease and well-developed technology is likely to contribute to the growth of the market.
Europe is expected to hold the second largest position in the global alagille syndrome market. The market growth in this region is attributed to the growing prevalence of several liver diseases, increasing prevalence of genetic disease, availability of funds for research, and increasing healthcare expenditure. According to the Public Health England, approximately 11,597 number of people died with an underlying cause of liver disease in England in 2014. In addition, according to the Office for National Statistics, gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in 2016.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, growing occurrences of rare diseases and increasing government funding for the healthcare sector.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Get Discount @ https://www.marketresearchfuture.com/check-discount/6324
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar